Ronald Levy, MD

Clinical Trials

• Recruiting Phase I/II of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL
• Not Recruiting Efficacy and Safety Study or Fostamatinib Disodium Tablets to Treat B-cell Lymphoma
• Not Recruiting Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma
• Recruiting A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab
• Recruiting Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma and Hodgkin's Disease
• Recruiting Genes in Predicting Outcome of Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab and Combination Chemotherapy
• Not Recruiting Phase I/II Study of Intratumoral Injection of CPG 7909, a TLR9 Agonist, Combined With Local Radiation for Patients With Recurrent Mycosis Fungoides.
• Recruiting Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
• Not Recruiting Vaccine Therapy for Multiple Myeloma Utilizing Idiotype-Pulsed Allogeneic Dendritic Cells
• Not Recruiting High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplant for Non-Hodgkin's Lymphoma
• Not Recruiting Phase I/II CPG 7909 + Local XRT in Recurrent Low-Grade Lymphomas
• Not Recruiting Personalized Active Immunotherapy (Vaccine Therapy) and Sargramostim Given After Standard of Care Treatment With Rituximab and Chemotherapy for Initial Treatment With Lymphoma
• Not Recruiting Vaccine Therapy and GM-CSF in Treating Patients With Progressive Non-Hodgkin's Lymphoma
• Not Recruiting A Phase II Intratumoral Injection PF-3512676 Plus Local Radiation in Low-Grade B-Cell Lymphomas
• Not Recruiting Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment
• Not Recruiting Safety and Efficacy Study of an Anti-CD20 Monoclonal Antibody (AME-133v) to Treat Non-Hodgkin's Lymphoma
• Not Recruiting Study of Bexxar Combined With External Beam Radiation Therapy for Patients With Relapsed, Bulky Non-Hodgkin's Lymphoma
• Recruiting Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation (HCT)
• Not Recruiting Safety and Efficacy Study of CAL-101 in Patients With Previously Treated Low-grade Lymphoma
• Not Recruiting VTX-2337 in Combination With Radiotherapy in Patients Low-Grade B-cell Lymphomas